(2026). CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing. Cancer Management and Research.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing."
Cancer Management and Research 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing."
Cancer Management and Research, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.